23
Jul
Jul
Comment: expanding benefits from GLP-1 drugs. Image loan: alexander_p / shutterstock In a recent article of comments published in the journal Medical reportsAuthors Maria J. Gonzalez-Rellan, Daniel J. Drucker from Mt. Sinai Hospital, Toronto, Canada summarize and explain the evidence that the Peptid-1 (GLP-1) receptor agonists (RAS), initially developed for the treatment of type 2 […]